Two papers that appeared in a recent issue of The Journal, one by Hagedorn and his associates1 of the Steno Memorial Institute of Copenhagen, the other by Root, White, Marble and Stotz2 of the New England Deaconess Hospital, have aroused widespread interest in insulin protamine compound. This new remedy for diabetes already has been distributed to a good many physicians and soon will be on the market and available to all. For this reason it seems to be desirable to make available to others the experience that we have had with it.
The Danish investigators found that insulin, precipitated from solutions of insulin hydrochloride with monoprotamine compounds and suitably buffered, was relatively insoluble in tissue fluids so that its absorption was delayed and its action correspondingly prolonged. They demonstrated that such insulin facilitated the management of cases of severe diabetes as indicated by smaller fluctuations of the sugar